[The consensus of the diagnosis and treatment of Castleman disease in China (2021)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2021 Jul 14;42(7):529-534. doi: 10.3760/cma.j.issn.0253-2727.2021.07.001.
Abstract
摘要
相似文献
1
[The consensus of the diagnosis and treatment of Castleman disease in China (2021)].
Zhonghua Xue Ye Xue Za Zhi. 2021 Jul 14;42(7):529-534. doi: 10.3760/cma.j.issn.0253-2727.2021.07.001.
2
Castleman-Kojima disease in a South Asian adolescent.
J Clin Exp Hematop. 2014;54(2):163-6. doi: 10.3960/jslrt.54.163.
3
Diagnosis and Management of Castleman Disease.
J Natl Compr Canc Netw. 2019 Nov;17(11.5):1417-1419. doi: 10.6004/jnccn.2019.5037.
4
Preoperative embolization as an adjunct to the operative management of mediastinal Castleman disease.
J Pediatr Surg. 2003 Sep;38(9):E21-3. doi: 10.1016/s0022-3468(03)00421-4.
5
[Progress in the diagnosis and treatment of Castleman disease].
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):697-700. doi: 10.3760/cma.j.issn.0253-2727.2020.08.017.
6
Diagnosis and management of Castleman disease.
Cancer Control. 2014 Oct;21(4):266-78. doi: 10.1177/107327481402100403.
7
Unicentric Castleman Disease.
Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73. doi: 10.1016/j.hoc.2017.09.006.
8
[Castleman disease].
An Pediatr (Barc). 2005 Jul;63(1):68-71. doi: 10.1157/13076770.
9
Castleman Disease.
Hematol Oncol Clin North Am. 2018 Feb;32(1):xiii-xiv. doi: 10.1016/j.hoc.2017.10.001.
10
A case of idiopathic multicentric Castleman disease presenting with diffuse lung cysts: how to evaluate treatment response?
Ann Hematol. 2020 Jun;99(6):1401-1402. doi: 10.1007/s00277-020-04030-5. Epub 2020 May 7.
引用本文的文献
1
[Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report].
Zhongguo Dang Dai Er Ke Za Zhi. 2025 May 15;27(5):613-617. doi: 10.7499/j.issn.1008-8830.2412050.
2
F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease.
Cancer Imaging. 2025 Feb 12;25(1):12. doi: 10.1186/s40644-025-00833-9.
3
Quality of life after idiopathic multicentric Castleman disease in China: a cross-sectional, multi-center survey of patient reported outcome and caregiver reported outcome.
Orphanet J Rare Dis. 2024 Dec 19;19(1):469. doi: 10.1186/s13023-024-03450-0.
4
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Lancet Reg Health West Pac. 2023 Mar 24;34:100720. doi: 10.1016/j.lanwpc.2023.100720. eCollection 2023 May.
本文引用的文献
1
UCD with MCD-like inflammatory state: surgical excision is highly effective.
Blood Adv. 2021 Jan 12;5(1):122-128. doi: 10.1182/bloodadvances.2020003607.
2
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334.
3
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.
Oncologist. 2020 Nov;25(11):963-973. doi: 10.1634/theoncologist.2019-0986. Epub 2020 Sep 18.
4
Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Blood. 2019 Apr 18;133(16):1720-1728. doi: 10.1182/blood-2018-11-884577. Epub 2019 Feb 13.
5
Recurrent PDGFRB mutations in unicentric Castleman disease.
Leukemia. 2019 Apr;33(4):1035-1038. doi: 10.1038/s41375-018-0323-6. Epub 2019 Jan 3.
6
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
7
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
Ann Hematol. 2018 Sep;97(9):1641-1647. doi: 10.1007/s00277-018-3347-0. Epub 2018 May 7.
8
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.
Cancer Sci. 2018 Jan;109(1):199-206. doi: 10.1111/cas.13439. Epub 2017 Dec 28.
9
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Blood. 2017 Mar 23;129(12):1658-1668. doi: 10.1182/blood-2016-11-748855. Epub 2017 Jan 18.
10
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.
Zotero 插件